SGIOF - GSK/Pfizer's Apretude approved as long-acting injectable HIV PrEP treatment

The FDA has approved ViiV Healthcare's Apretude (cabotegravir) as the first long-acting, injectable HIV treatment for pre-exposure prophylaxis (PrEP). Apretude can be administered as infrequently as six times per year. ViiV said that Vocabria (cabotegravir tablets) may be administered for about a month before initiating the first injection to assess the tolerability of Apretude. ViiV is majority owned by GlaxoSmithKline (NYSE:GSK), with Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOF) as minority shareholders. In October, ViiV submitted an application to the FDA for Triumeq (abacavir/ dolutegravir/ lamivudine) in a dispersible tablet formulation.

For further details see:

GSK/Pfizer's Apretude approved as long-acting, injectable HIV PrEP treatment